Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis

https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.095

Full Text:

Abstract

Objective: to perform cost-effectiveness analysis of the treatment for adult patients with psoriatic arthritis (PsA) with a Russian interleukin- 17А inhibitor netakimab in comparison with other biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and to evaluate the influence of the inclusion of netakimab in the therapy for PsA on the budget of the Russian healthcare system.

Material and methods. The evaluation of cost-effectiveness was performed from the position of the Russian healthcare system for patients with moderate and severe PsA. The evaluation was performed based on the results of the network meta-analysis of the randomized clinical studies. The criterion of clinical effectiveness included the changes in the condition of the joints by the criteria of the American College of Rheumatology (ACR20, ACR50, and ACR70) and changes in skin symptoms by the index of the prevalence and severity of psoriasis (PASI 75 and PASI 90) with a recalculation into quality-adjusted life-year (QALY). The time horizon of the cost-effectiveness analysis was 2 years. The calculation was based on the registered prices and VAT. If there was an original drug and a biosimilar registered on the pharmaceutical market, the calculation was based on the median of the registered prices. The budget impact analysis of the influence of netakimab inclusion in the therapy for patients with PsA was performed considering the structure of the prescription of bDMARDs and tsDMARDs that was determined in the pharmaco-epidemiological study conducted in the Russian Federation in 2020. The analysis was performed for patients that received medication by the scheme of reimbursement. The time horizon of the study was 3 years old.

Results. In the base-case analysis, the cost-effectiveness ratio for netakimab was 1.210 mln rub/QALY (by 66.2–88.5% lower than in cases when comparison drugs were used). The budget impact analysis showed that the inclusion of netakimab in the therapy for PsA could reduce the costs by 376.60 mln rub (21.1%). Considering budget saving, the number of additional patients that can be treated will increase by 26.7% within 3 years.

Conclusion. Netakimab is characterized by higher cost-effectiveness in comparison with other bDMARDs (adalimumab, golimumab, guselkumab, ixekizumab, infliximab, secukinumab, ustekinumab, certolizumab pegol, etanercept) and tsDMARDs (apremilast, tofacitinib) prescribed in the Russian Federation for patients with PsA. The inclusion of netakimab in the therapy for PsA will reduce the financial burden on the healthcare system.

About the Authors

A. V. Rudakova
Saint Petersburg State Chemical Pharmaceutical University
Russian Federation

Alla V. Rudakova – Dr. Pharm. Sc., Professor, Chair of Pharmacy Management and Economics. Scopus Author ID: 6603725182; RSCI SPIN-code: 3178-2814

14 lit. A Professor Popov Str., Saint Petersburg 197376, Russia



D. G. Tolkacheva
Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Darya G. Tolkacheva – Independent Expert of Research Projects, Project Office

82 Vernadskiy Prosp., Moscow 119571, Russia



V. D. Sokolova
Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Valeriya D. Sokolova – Independent Expert of Research Projects, Project Office

82 Vernadskiy Prosp., Moscow 119571, Russia



References

1. Korotaev T.V., Korsakova Yu.I. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Rheumatology Science and Practice. 2018; 56 (1): 60–9 (in Russ.). https://doi.org/10.14412/1995-4484-2018-60-69.

2. Gladman D.D., Antoni C., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 (Suppl. 2): ii14–7. https://doi.org/10.1136/ard.2004.032482.

3. Schlueter M., Finn E., Díaz S., et al. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. Clinicoecon Outcomes Res. 2019; 11: 395–403. https://doi.org/10.2147/CEOR.S201621.

4. Hidalgo-Vega Á., Villoro R., Blasco J.A., et al. Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Eff Resour Alloc. 2015; 13: 11. https://doi.org/10.1186/s12962-015-0037-9.

5. Hendrix N., Ollendorf D.A., Chapman R.H., et al. Cost-effectiveness of targeted pharmacotherapy for moderate to severe plaque psoriasis. J Manag Care Spec Pharm. 2018; 24 (12): 1210–7. https://doi.org/10.18553/jmcp.2018.24.12.1210.

6. Tolkacheva D.G., Mladov V.V., Sokolova V.D. Efficacy of biologics and targeted synthetic drugs approved in Russia to treat adults with active psoriatic arthritis: a systematic review and network metaanalysis. Medical Technologies. Assessment and Choice. 2021; 2: 51–66. https://doi.org/10.17116/medtech20214302151.

7. Lila A.M., Dreval R.О., Shipitsyn V.V. Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation. Modern Rheumatology Journal. 2018; 12 (3): 112–9 (in Russ.). https://doi.org/10.14412/1996-7012-2018-3-112-119.


For citation:


Rudakova A.V., Tolkacheva D.G., Sokolova V.D. Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(2):116–123. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.095

Views: 260


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)